Wedbush Lowers Vigil Neuroscience (NASDAQ:VIGL) Price Target to $13.00

Vigil Neuroscience (NASDAQ:VIGL) had its price objective cut by Wedbush from $24.00 to $13.00 in a report issued on Friday morning,Benzinga reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for Vigil Neuroscience’s FY2029 earnings at $1.40 EPS.

Other research analysts also recently issued reports about the company. Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a research note on Friday, January 24th. JMP Securities restated a “market outperform” rating and set a $22.00 price objective on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. William Blair initiated coverage on Vigil Neuroscience in a research note on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, HC Wainwright lowered their price objective on Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a research note on Friday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $16.25.

Vigil Neuroscience Trading Down 4.3 %

Shares of NASDAQ VIGL opened at $2.02 on Friday. Vigil Neuroscience has a twelve month low of $1.49 and a twelve month high of $6.06. The company has a market capitalization of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82. The business has a 50 day simple moving average of $2.34 and a 200-day simple moving average of $2.78.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). As a group, equities analysts predict that Vigil Neuroscience will post -2.07 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in VIGL. Walleye Capital LLC boosted its position in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock worth $407,000 after acquiring an additional 92,217 shares during the period. Verition Fund Management LLC acquired a new position in Vigil Neuroscience during the 3rd quarter worth $442,000. Point72 Asset Management L.P. boosted its position in Vigil Neuroscience by 7.7% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,600,000 shares of the company’s stock worth $5,440,000 after acquiring an additional 115,000 shares during the period. Geode Capital Management LLC lifted its holdings in shares of Vigil Neuroscience by 41.9% in the third quarter. Geode Capital Management LLC now owns 226,083 shares of the company’s stock valued at $769,000 after buying an additional 66,712 shares during the period. Finally, abrdn plc lifted its holdings in shares of Vigil Neuroscience by 124.9% in the fourth quarter. abrdn plc now owns 528,472 shares of the company’s stock valued at $898,000 after buying an additional 293,461 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.